31430-38-3

Usage

Uses

Used in Organic Synthesis:
1-(5-Bromo-2-pyridyl)-2-thiourea is utilized as a key building block in the synthesis of a range of biologically active compounds, contributing to the development of new pharmaceutical agents.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(5-Bromo-2-pyridyl)-2-thiourea is employed as a precursor in the formulation of drug molecules, leveraging its hydrogen bonding capabilities to enhance molecular interactions and stability.
Used in Drug Development:
1-(5-Bromo-2-pyridyl)-2-thiourea is applied in drug development for its potential to form the basis of new therapeutic agents, particularly due to its ability to engage in hydrogen bonding, which is crucial for the efficacy and selectivity of drug molecules.
Used in Biomedical Research:
1-(5-Bromo-2-pyridyl)-2-thiourea is also used in biomedical research to explore its potential anti-inflammatory and antioxidant properties, which could lead to the discovery of novel treatments for various diseases and conditions.

InChI:InChI=1/C6H6BrN3S/c7-4-1-2-5(9-3-4)10-6(8)11/h1-3H,(H3,8,9,10,11)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 1147550-11-5 ammonium thiocyanate 
• 31430-37-2 N-(5'-bromo-2'-pyridyl)-N'-benzoylthiourea 

Downstream Products

• 350511-12-5 (5-bromo-pyridine-2-yl)-thiazole-2-yl-amine 

Relevant academic research and scientific papers

PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS

Novel heterocyclic compounds of the formula (I) in which R1, R2, R3, R4 and D have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/o treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA

2-Amino-5-(thioaryl)thiazoles are potent inhibitors of TrkA (e.g., 20h, TrkA IC50 = 0.6 nM) that show anti-proliferative effect in cellular assays. A proposed inhibitor binding mode to TrkA active site is consistent with key SAR observations.

SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON

The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH 2 ; Y 1 , Y 2 , Y 3 , Y 4 and Y 5 , which may be identical or different, are each CH or N; however, at least one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N; Z 1 and Z 2 , which may be identical or different, are each CH or N; n is an integer from 1 to 3; R 1 is a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R 2 and R 3 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aromatic heterocyclic ring, or the like; and R 4 is a hydrogen atom, a lower alkyl group, a C 3 -C 6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.

Tyrosine kinase inhibitors

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.